Johns Hopkins Opens First U.S. Clinic to Treat Psychedelic Side Effects

As psychedelic therapies gain mainstream acceptance and federal research support expands, Johns Hopkins University has opened the first clinic in the United States specifically dedicated to treating rare but serious long-term side effects from psychedelic use. The Clinic for Post-Psychedelic Difficulties, launched last year at the Baltimore institution renowned for its pioneering psychedelic research, represents a critical evolution in the field—acknowledging that while these substances show remarkable therapeutic promise, they are not without risks that require specialized medical attention.

The clinic's establishment comes at a pivotal moment. Recent surveys indicate a majority of Americans now support psychedelic use for medical purposes, and the Trump administration issued an executive order in April directing federal agencies to accelerate research into psychedelic therapies for mental health conditions. Psilocybin and MDMA have demonstrated particular promise in treating post-traumatic stress disorder and treatment-resistant depression, leading to expanded clinical trials and state-level legalization efforts in Oregon and Colorado.

Treating the Rare but Real Harms

Psychiatrist Azin Bekhrad, who co-founded and directs the Johns Hopkins clinic, says the facility serves two primary patient populations. Some individuals experience manic or psychotic episodes following psychedelic use, occasionally complicated by concurrent substance use including alcohol. These cases can represent acute psychiatric emergencies requiring immediate intervention and ongoing management.

The second and more prevalent category involves patients suffering from hallucinogen persisting perception disorder, commonly known as HPPD. This rare condition manifests as persistent visual disturbances long after the acute psychedelic effects have subsided. Patients report visual snow, halos around objects, geometric shapes superimposed on their visual field, and other perceptual anomalies that can prove deeply distressing and interfere with daily functioning.

"It's not just the flashback, not just the traumatic sort of experience, but paired with persistent visual problems," Bekhrad explained in describing the condition's severity. These symptoms can persist for months or even years, with some patients suffering for decades before finding appropriate care.

A Growing Clinical Network

The Johns Hopkins clinic treated ten patients in its first year of operation, offering in-person visits and limited telehealth services for Maryland residents. While these numbers appear modest, they represent a significant step forward for a condition that has historically gone unrecognized and untreated within mainstream psychiatry.

Emory University in Atlanta is expected to open a similar clinic this year, according to university officials, suggesting the beginning of a specialized treatment infrastructure across major academic medical centers. These American facilities join a small but established clinic in Berlin, founded in 2017, which typically sees between 150 and 200 patients annually and provides telehealth consultations to individuals worldwide.

Dr. Tomislav Majić, the Berlin clinic's director, notes that many patients suffer for years simply because they do not know where to seek help or that treatment exists at all. The emergence of dedicated clinics addresses this knowledge gap while building clinical expertise in managing conditions that general psychiatrists may rarely encounter.

Treatment Approaches and Outcomes

Treatment protocols for post-psychedelic difficulties draw from case studies published in the late 1990s and have more recently been validated through larger clinical trials. The therapeutic approach typically combines antidepressant medications with antiseizure drugs, tailored to individual symptom profiles.

Research suggests these regimens produce meaningful results. Approximately one-third of patients achieve full recovery within a year of beginning treatment, while others experience significant symptom reduction. For HPPD specifically, early intervention appears particularly important, as prolonged symptoms can become more resistant to treatment over time.

The clinics also serve a broader research function, systematically documenting adverse events that have historically been underreported in psychedelic studies. This data collection addresses a significant gap in the scientific literature and may help identify risk factors that could predict which individuals are most vulnerable to persistent side effects.

Prevalence and Risk Factors

Determining exactly how common long-term psychedelic complications are remains challenging. Psychedelics are frequently used recreationally outside clinical settings, meaning adverse events often go unreported to medical authorities. One web-based survey estimated HPPD affects approximately 4.2 percent of psychedelic users, though this figure may undercount actual prevalence given the condition's subtle symptoms and limited awareness among both patients and providers.

A 2024 meta-analysis published in JAMA Psychiatry found that individuals with preexisting neuropsychiatric conditions account for about 4 percent of serious adverse events, suggesting that screening for mental health history may help identify higher-risk candidates for psychedelic therapy. However, HPPD can occur even in individuals without prior psychiatric diagnoses, and manic episodes have been documented in people with no history of bipolar disorder.

Dr. Majić suggests the stigma surrounding adverse event reporting may contribute to undercounting. Researchers understandably fear that emphasizing psychedelic risks could trigger regulatory backlash similar to the 1970s prohibition that effectively halted scientific inquiry for decades. Yet maintaining credible research requires honest accounting of both benefits and harms.

"What is lacking, in my view, is a really balanced and nonideological perspective on the substances," Majić observed. "On the one hand, they are not toxic, and they're not addictive. On the other hand, they're not without risks."

Implications for Psychedelic Policy

The emergence of specialized clinics for psychedelic side effects carries important implications for ongoing policy debates. As states consider legalization and the federal government expands research programs, understanding the full risk profile becomes essential for informed decision-making.

Proponents of psychedelic therapy argue that establishing treatment infrastructure for rare adverse events represents responsible medicine—acknowledging and managing risks rather than allowing them to remain hidden. The existence of these clinics may actually strengthen the case for regulated psychedelic access by demonstrating that medical systems can address potential harms.

Critics, however, may point to the need for specialized treatment as evidence that psychedelics require stricter oversight than advocates suggest. The line between acceptable risk and unacceptable harm remains contested, particularly when vulnerable populations including adolescents or individuals with psychotic spectrum disorders may face heightened vulnerability.

For individuals experiencing treatment-resistant depression or PTSD who have exhausted conventional options, psychedelic therapies may offer genuine hope. The growing network of post-psychedelic care ensures that the small percentage who experience complications have somewhere to turn. As research continues and clinical experience accumulates, these specialized clinics will play an essential role in developing evidence-based approaches to both harnessing psychedelic benefits and managing their risks.